natgillin/translations-raw huggingface dataset:
It is recommended that the animal be distracted for several minutes following treatment to prevent licking (oral absorption of the cream is not harmful to the dog, but removal of the cream by licking directly after treatment might decrease efficacy). 
Žival je nekaj minut po nanašanju priporočljivo zamotiti, da se ne liže (peroralna absorpcija kreme psu ne škoduje, vendar pa se zmanjša njena učinkovitost, če kremo odstrani takoj po nanašanju).
6.4 Nature and composition of immediate packaging Collapsible aluminium tube containing 15 g cream, sealed with aluminium and closed with a polyethylene screw cap, packed in cardboard boxes, one tube per box. 
1 zložljiva aluminijasta tuba s 15 g kreme, zatesnjena z aluminijasto zaporko in zaprta z navojno zaporko iz polietilena; zloženke z eno tubo.
Its mineralocorticoid and progestational activity is very low. 
Njegov mineralokortikoidni in progestacijski učinek je zelo šibak.
The therapeutic use of these substances in humans has been recognised to induce local side effects such as skin thinning, skin weakness, delayed healing process and secondary infections. 
Pri terapevtski uporabi teh snovi pri ljudeh so ugotovili, da imajo lokalne neželene učinke, kot so na primer tanjšanje kože, ohlapnost kože, upočasnjeno celjenje in sekundarne okužbe.
4.7 Use during pregnancy and lactation 
4.7 Uporaba v obdobju brejosti in laktacije
Resocortol butyrate has local and systemic glucocorticoid effects. 
Resokortol butirat ima lokalne in sistemske glukokortikoidne učinke.
11 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 
PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE Navedba ni smiselna.
Do not use in dogs with extensive lesions. 
Ne uporabite pri psih z obsežnimi poškodbami.
Since glucocorticosteroids can slow growth, use in young, growing animals should be well controlled and large lesions should not be treated. 
Ker lahko glukokortikosteroidi upočasnijo rast, moramo njihovo uporabo pri mladih živalih, ki še rastejo, skrbno nadzorovati in jih ne uporabljati za zdravljenje velikih poškodb.
After oral administration in dogs few systemic effects were observed. 
Po peroralnem dajanju so pri psih zasledili malo sistemskih učinkov.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THEMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROSTITEV SERIJ V EGP, ČE STA RAZLIČNA
In case of diabetes mellitus, the potential systemic effects of the product may influence glycaemia. 
Pri živalih s sladkorno boleznijo (diabetes mellitus) lahko morebitni sistemski učinki zdravila vplivajo na glikemijo.
6.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from such medicinal products 
6.5 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi, ki nastanejo iz teh zdravil
4.1 Target species 
4.1 Ciljna živalska vrsta
ANNEX III LABELLING AND PACKAGE INSERT 
DODATEK III OZNAČEVANJE IN NAVODILO ZA UPORABO
Overdosing, i.e. application rate of more than twice a day, or extension of the duration of treatment, increases the risk of glucocorticoid systemic effects particularly when administered on extensive lesions. 
pogostnejša uporaba kot 2-krat na dan ali podaljšanje zdravljenja, poveča nevarnost glukokortikoidnih sistemskih učinkov, zlasti kadar zdravilo uporabljamo na večjem predelu.
Shelf life after first opening of the tube: 8 weeks 
Rok uporabnosti po prvem odpiranju vsebnika: 8 tednov
Resocortol butyrate is a corticosteroid which has a high intrinsic glucocorticoid activity. 
Resokortol butirat je kortikosteroid z visoko intrinzično glukokortikoidno aktivnostjo.
EXPIRY DATE Month/Year 
DATUM IZTEKA ROKA UPORABNOSTI Mesec/leto
D. STATEMENT OF THE MRLs Not applicable. 
D. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN ZAOSTANKOV ZDRAVILA (MRL) Navedba ni smiselna.
To be supplied only on veterinary prescription. 
Uporablja se le na osnovi veterinarskega recepta..
SPECIAL STORAGE CONDITIONS Do not store above 25 °C 
POSEBNA NAVODILA ZA SHRANJEVANJE Ne shranjujte pri temperaturi nad 25 ºC.
4.10 Overdose 
4.10 Preveliko odmerjanje
THE WORDS "FOR ANIMAL TREATMENT ONLY" For animal treatment only 
BESEDILO ''SAMO ZA ŽIVALI'' Samo za živali
TARGET SPECIES 
CILJNA ŽIVALSKA VRSTA
On rare occasions hyperaemia of the treated area has been observed. 
Redko so na zdravljenem predelu zapazili hiperemijo.
For topical administration to the skin. 
Za lokalno uporabo na koži.
This product belongs to the class of dermocorticoids. 
Zdravilo sodi v skupino dermokortikoidov.
Not applicable. 
Navedba ni smiselna.
Do not use in dogs with infected lesions of bacterial, viral, fungal or parasitic origin or with ulcerated lesions. 
Ne uporabite pri psih z okužbami poškodb bakterijskega, virusnega, glivičnega ali parazitskega izvora, ali razjedami.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS IF ANY 
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
After topical application on the skin, a local anti-inflammatory effect is seen, which is accompanied by a moderate and reversible adrenal suppression at higher doses. 
Po nanašanju na kožo ima zdravilo lokalni protivnetni učinek, ki ga pri uporabi večjih odmerkov spremlja zmerna in reverzibilna supresija nadledvične žleze.
4.6 Adverse reactions (frequency and seriousness) On rare occasions hyperaemia of the treated area has been observed. 
4.6 Neželeni učinki (pogostnost in resnost)
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION 
ODMERJANJE ZA POSAMEZNE ŽIVALSKE VRSTE TER NAČIN UPORABE IN
SPECIAL WARNINGS 
POSEBNA OPOZORILA
Wearing disposable gloves, apply the cream gently to the lesion. 
Nadenite si rokavice za enkratno uporabo in kremo nežno nanesite na prizadeto mesto.
Clean the affected areas and clip the hair covering the lesions before application. 
Pred uporabo prizadete predele očistite in odstrizite dlako.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Resocortol butyrate 1mg/g 
NAVEDBA ZDRAVILNE UČINKOVINE IN DRUGIH SNOVI Resokortol butirat, 1 mg/g
Once broached, use within 8 weeks 
Načeto/odprto zdravilo uporabite v 8 tednih.
STATEMENT OF THE ACTIVE SUBSTANCE Resocortol butyrate: 1mg/g 
NAVEDBA UČINKOVINE Resokortol butirat: 1 mg/g
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
QUANTITY OF THE ACTIVE SUBSTANCE Resocortol butyrate 1 mg/g 
KOLIČINA ZDRAVILNE UČINKOVINE Resokortol butirat, 1 mg/g
During initial treatment apply the cream twice daily. 
Na začetku zdravljenja nanašajte kremo dvakrat na dan. Zdravite 7 do 14 dni.
Wear disposable gloves when applying the product. 
Ko izdelek nanašate, nosite rokavice za enkratno uporabo.
Do not use in dogs used for breeding and in lactating or pregnant bitches. 
Ne uporabite pri psih, ki so namenjeni vzreji, in pri doječih ali brejih psicah.
Pruban contains the active principle resocortol butyrate. 
Pruban vsebuje zdravilno učinkovino resokortol butirat.
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH 
A. IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
CONDITIONS OF THE MARKETING AUTHORISATION INCLUDING RESTRICTIONS REGARDING SUPPLY AND USE 
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 15 g 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV
Treatment of acute localised moist dermatitis. 
Zdravljenje akutnega, lokaliziranega vlažnega dermatitisa
INDICATION Treatment of acute localised moist dermatitis. 
INDIKACIJA Zdravljenje akutnega, lokaliziranega vlažnega dermatitisa.
Veterinary medicinal product subject to prescription. 
Izdaja zdravila za uporabo v veterinarski medicini je le na recept.
Not applicable 
NEŽELENI UČINKI
B. PACKAGE INSERT 
B. NAVODILO ZA UPORABO
6.3 Special precautions for storage 
4.5 Posebni previdnostni ukrepi
QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s) 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Zdravilna(e) učinkovina(e) Resokortol butirat
INDICATION(S) Treatment of acute localised moist dermatitis. 
INDIKACIJE Zdravljenje akutnega, lokaliziranega vlažnega dermatitisa.
Apply to the affected skin by gently applying it to the lesion. 
Nežno nanesite na prizadeti predel kože.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO
THE WORDS "KEEP OUT OF REACH AND SIGHT OF CHILDREN" Keep out of reach and sight of children 
BESEDILO “ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM ”
STATEMENT OF THE MRLs 
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN ZAOSTANKOV ZDRAVILA (MRL)
ROUTE(S) OF ADMINISTRATION Cutaneous use. 
NAČIN(I) UPORABE ZDRAVILA Dajanje na kožo in kožne tvorbe.
30 June 2024 
30. junij 2024
Submission of study results: 
Predložitev rezultatov študije:
A risk to the suckling child cannot be excluded. 
Tveganja za dojenega otroka ne moremo izključiti.
pH: 5.0 to 6.0 
pH: od 5,0 do 6,0.
You will only be given this medicine if the possible benefit is greater than the possible risks. 
To zdravilo boste prejeli le, če je morebitna korist večja od morebitnih tveganj.
It has not been tested in other types of shock. 
Niso ga preskušali pri nobeni drugi vrsti šoka.
If this occurs, hospital staff will monitor your vital signs and you will be provided with supportive care. 
Če pride do tega, bo bolnišnično osebje spremljalo vaše vitalne znake in vam nudilo podporno oskrbo.
Millmount Healthcare Limited Block 7, City North Business Campus Stamullen, Co. Meath Ireland 
Millmount Healthcare Limited Block 7, City North Business Campus Stamullen, Co. Meath Irska
From a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega vidika je treba zdravilo uporabiti takoj.
Final concentration (ng/mL) 
Končna koncentracija (ng/ml)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve:
One patient in each arm discontinued treatment as a result. 
Po en bolnik iz vsake skupine je zaradi tega prekinil zdravljenje.
38/58 patients mITT=modified intent-to-treat population 
38/58 bolnikov mITT = modificirana populacija z namenom zdravljenja
Median age was 64 years (range: 22-89 years). 
Mediana starost je bila 64 let (razpon: 22-89 let).
4.7 Effects on ability to drive and use machines Not relevant. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Podatek ni potreben.
Use of this medicine during pregnancy should be avoided if possible. 
Če je le mogoče, se je treba uporabi tega zdravila med nosečnostjo izogibati.
These types of symptoms occur in greater than 1 out of every 10 patients. 
Tovrstni simptomi se pojavijo pri več kot 1 od
The dose depends on your body weight. 
Odmerek je odvisen od vaše telesne mase.
Mechanism of action and pharmacodynamic effects 
Mehanizem delovanja in farmakodinamični učinki
The effect on MAP was sustained for at least the first three hours of treatment. 
Učinek na MAP se je ohranil vsaj prve tri ure zdravljenja.
91% of subjects had septic shock; the remaining subjects had other forms of distributive shock such as neurogenic shock. 
91 % preiskovancev je imelo septični šok; preostali preiskovanci so imeli druge oblike distribucijskega šoka, kot je nevrogeni šok.
Fluid Restricted? 
Omejen vnos tekočin?
Your doctor may already be giving you other medicines used to increase your blood pressure. 
Zdravnik vam morda že daje druga zdravila, ki se uporabljajo za zviševanje krvnega tlaka.
Osmolarity: 130 to 170 mOsm/kg 
Osmolarnost: od 130 do 170 mOsm/kg.
Storage conditions 
Pogoji shranjevanja
The effect on blood pressure is sustained for at least the first three hours of continuous intravenous infusion. 
Učinek na krvni tlak se ohrani vsaj prve tri ure neprekinjene intravenske infuzije.
Do not use this medicine after the expiry date which is stated on the carton and vial after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in viali poleg oznake „EXP“.
The effect of GIAPREZA on morbidity and mortality has not been determined in appropriate studies. 
Učinka zdravila GIAPREZA na obolevnost in smrtnost niso ugotavljali v ustreznih študijah.
Your doctor will continue to assess your response and will adjust the dose accordingly up to a maximum of 80 ng per kilogram each minute during the first 3 hours of treatment. 
Zdravnik bo še naprej ocenjeval vaš odziv in bo skladno z njim prilagodil odmerek do največ 80 ng na kilogram na minuto v prvih treh urah zdravljenja.
Primary efficacy endpoints: MAP response at hour 3 (mITT population and subgroups) 
Preglednica 3: Primarni opazovani dogodki učinkovitosti: Odziv MAP po 3 urah (populacija mITT in podskupine)
For critically ill patients, the usual target mean arterial pressure is 65 - 75 mmHg. 
Pri kritično bolnih bolnikih je običajni ciljni povprečni arterijski tlak 65-75 mmHg.
In the ATHOS-3 trial, the median time to increase blood pressure was approximately 5 minutes. 
V preskušanju ATHOS-3 je bil mediani čas do zvišanja krvnega tlaka približno 5 minut.
Your doctor should be told if you are using, have recently used, or might use any other medicines. 
Obvestite zdravnika, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
Store in a refrigerator (2-8 °C). 
Shranjujte v hladilniku (2-8 °C).
The median duration of treatment in clinical trials was 48 hours (range: 3.5 to 168 hours). 
Mediano trajanje zdravljenja v kliničnih preskušanjih je bilo 48 ur (razpon: od 3,5 do 168 ur).
Read all of this leaflet carefully before you are given this medicine because it contains important information for you. 
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
This leaflet was last revised in MM/YYYY. 
Navodilo je bilo nazadnje revidirano dne MM/LLLL.
You will be monitored closely to make sure that your blood pressure is at the right level. 
Skrbno vas bodo spremljali in se prepričali, da je vaš krvni tlak na pravi ravni.
The diluted solution should be used immediately. 
Razredčeno raztopino je treba uporabiti takoj.
What you need to know before you are given GIAPREZA 3. 
Kaj morate vedeti, preden boste prejeli zdravilo GIAPREZA 3.
However, if you have side effects or think you have been given too much GIAPREZA, tell your doctor or nurse straight away. 
Če pa imate neželene učinke ali menite, da ste prejeli prevelik odmerek zdravila GIAPREZA, takoj obvestite zdravnika ali medicinsko sestro.
There are no data available on the potential effects on fertility in humans. 
Podatkov o možnih učinkih na plodnost pri ljudeh ni.
GIAPREZA should not be used in children or adolescents under 18 years of age as it has not been studied in these age groups. 
Otroci in mladostniki Zdravila GIAPREZA se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let, ker ga v teh starostnih skupinah niso preučevali.
Patients with cardiogenic shock were excluded (see section 4.4). 
Bolniki s kardiogenim šokom so bili izključeni (glejte poglavje 4.4).
114/163 patients 
114/163 bolnikov
Overdose may result in severe hypertension. 
Zaradi prevelikega odmerjanja lahko pride do hude hipertenzije.
No treatment related adverse effects were observed. 
Neželenih učinkov, povezanih z zdravljenjem, niso opazili.
What you need to know before you are given GIAPREZA You must not be given GIAPREZA: - if you are allergic to angiotensin II or any of the other ingredients of this medicine (listed in section 6). 
Kaj morate vedeti, preden boste prejeli zdravilo GIAPREZA Zdravila GIAPREZA ne smete prejeti: - če ste alergični na angiotenzin II ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
BATCH NUMBER Lot: 
ŠTEVILKA SERIJE Lot:
Of these, 7 cases corresponded to deep vein thrombosis. 
Med njimi je bilo 7 primerov globoke venske tromboze.
GIAPREZA was tested in a small amount of patients more than 75 years of age. 
Zdravilo GIAPREZA so preskušali pri manjšem številu bolnikov, starejših od 75 let.
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1384/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM EU/1/19/1384/001
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 - 8 °C or 25 °C. 
Če zdravila ne uporabite takoj, je za čas shranjevanja med uporabo in pogoje pred uporabo odgovoren uporabnik; ta čas ne sme biti daljši od 24 ur pri temperaturi 2-8 ºC ali 25 °C.
GIAPREZA is used in an emergency setting to increase blood pressure to normal levels in adult patients with seriously low blood pressure who do not respond to fluids or other medicines that raise blood pressure. 
Zdravilo GIAPREZA se uporablja v nujnih primerih za zviševanje krvnega tlaka na normalno raven pri odraslih bolnikih z resno znižanim krvnim tlakom, ki se ne odzivajo na tekočine ali druga zdravila za zviševanje krvnega tlaka.
While not all of these symptoms lead to life-threatening complications, your doctor should be told about them immediately. 
Vsi ti simptomi sicer ne privedejo do smrtno nevarnih zapletov, kljub temu pa morate o njih takoj obvestiti zdravnika.
Of the 114 responders at Hour 3, only 2 (1.8%) received more than 80 ng/kg/min. 
Od 114 odzivnih bolnikov po treh urah sta le dva (1,8 %) prejela več kot 80 ng/kg/min.
It is first diluted and then given as a drip (infusion) into a vein, supplying a specified dose each minute. 
Najprej ga bodo razredčili in ga nato dali v obliki kapalne infuzije (infundiranja) v veno, s čimer boste vsako minuto prejeli določen odmerek.
The maximum dose after the first 3 hours will be 40 ng per kilogram each minute. 
Največji odmerek po prvih treh urah je 40 ng na kilogram na minuto.
It is metabolised by end terminal cleavage (at both the amino and carboxy termini) in a variety of tissues including erythrocytes, plasma and many of the major organs (ie, intestine, kidney, liver and lung). 
Presnavlja se s terminalno cepitvijo (na amino in karboksi koncu) v različnih tkivih, vključno z eritrociti, plazmo in številnimi glavnimi organi (tj. črevesjem, ledvicami, jetri in pljuči).
The adverse reactions described in this section were identified in the pivotal clinical study (N = 163 treated with GIAPREZA). 
Neželene učinke, opisane v tem poglavju, so zabeležili v ključni klinični študiji (N = 163 bolnikov, zdravljenih z zdravilom GIAPREZA).
As a part of your treatment, you may be given medicine to prevent the formation of blood clots. 
sklopu zdravljenja boste morda prejeli zdravilo za preprečevanje nastajanja krvnih strdkov.
Peripheral ischaemia may be a consequence of the mechanism of action of GIAPREZA. 
Periferna ishemija je lahko posledica mehanizma delovanja zdravila GIAPREZA.
Of the 321 patients treated in the Phase 3 study, 195 patients were male (60.7%), 257 (80%) patients were White, 33 (10%) were Black, and 31 (10%) were Other. 
Od 321 bolnikov, zdravljenih v študiji 3. faze, je bilo 195 (60,7 %) moških, 257 (80 %) belcev, 33 (10 %) temnopoltih in 31 (10 %) druge rase.
Your doctor or nurse should be told if any of the above applies to you before this medicine is used. 
Zdravniku ali medicinski sestri morate pred uporabo zdravila povedati, če kar koli od zgoraj navedenega velja za vas.
Mortality through day 28 was 46% on GIAPREZA and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57-1.07). 
Smrtnost do 28. dneva je bila 46 % pri zdravilu GIAPREZA in 54 % pri placebu (razmerje ogroženosti 0,78; 95-odstotni interval zaupanja 0,57-1.07).
Common side effects (may affect up to 1 in 10 people) are: - Rapid heartbeat - Poor circulation to your hands, feet, or other bodily areas which can be severe and cause tissue damage. 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) so: - hiter srčni utrip, - slaba prekrvavitev v dlaneh, stopalih ali drugih delih telesa, ki je lahko huda in povzroči poškodbe tkiv.
Diluted solution should be clear and colourless. 
Razredčena raztopina mora biti bistra in brezbarvna.
The clinical experience with GIAPREZA is limited to septic or other distributive shock. 
Klinične izkušnje z zdravilom GIAPREZA so omejene na septični ali drugačen distribucijski šok.
The use of GIAPREZA is not recommended in other types of shock (e.g.: cardiogenic shock, etc) as patients with non-distributive shocks were excluded from clinical trials (see section 5.1). 
Uporaba zdravila GIAPREZA ni priporočljiva pri drugih vrstah šoka (npr. kardiogenem šoku ipd.), saj so bili bolniki z nedistribucijskimi šoki izključeni iz kliničnih preskušanj (glejte poglavje 5.1).
Due to the short half-life of GIAPREZA (less than one minute), an abrupt withdrawal of angiotensin may lead to rebound hypotension (see section 4.4). 
Zaradi kratke razpolovne dobe zdravila GIAPREZA (manj kot ena minuta) lahko nenadna odtegnitev angiotenzina povzroči povratno hipotenzijo (glejte poglavje 4.4).
The effect of GIAPREZA when added to maximum doses of other vasopressors is unknown. 
Učinek zdravila GIAPREZA ob dodajanju največjim odmerkom drugih vazopresorjev ni znan.
GIAPREZA should be prescribed by a physician experienced in the treatment of shock and is intended for use in an acute and hospital setting. 
Zdravilo GIAPREZA sme predpisovati samo zdravnik z izkušnjami z zdravljenjem šoka in je namenjeno uporabi v akutnih primerih in v bolnišnici.
Your doctor will monitor your blood pressure and adjust your dose as needed. 
Zdravnik bo spremljal vaš krvni tlak in po potrebi prilagodil odmerek.
At the time of study drug administration, 97% of subjects were receiving norepinephrine, 67% vasopressin, 15% phenylephrine, 13% epinephrine, and 2% dopamine. 
V času dajanja študijskega zdravila je 97 % preiskovancev prejemalo norepinefrin, 67 % vazopresin, 15 % fenilefrin, 13 % epinefrin in 2 % dopamin.
Diluted solution may be stored at room temperature or under refrigeration. 
Razredčeno raztopino lahko shranjujete pri sobni temperaturi ali v hladilniku.
After the initial dose, your doctor will adjust the rate as often as every 5 minutes until you achieve your target blood pressure. 
Po začetnem odmerku bo zdravnik morda prilagajal odmerek tudi na vsakih 5 minut, dokler ne boste dosegli ciljnega krvnega tlaka.
Maintenance doses should not exceed 40 ng/kg per minute. 
Vzdrževalni odmerki ne smejo presegati 40 ng/kg na minuto.
Inspect each vial for particulate matter prior to dilution. 
Pred redčenjem vsako vialo preglejte glede prisotnosti delcev.
OTHER La Jolla Pharmaceutical 
DRUGI PODATKI La Jolla Pharmaceutical
Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature and 2-8 °C. 
Kemična in fizikalna stabilnost med uporabo je bila dokazana za 24 ur pri sobni temperaturi in temperaturi 2-8 ºC.
The treatment effect was consistent in high risk subsets of patients with low baseline MAP or high APACHE II score, which were stratification variables (Table 3). 
Učinek zdravljenja je bil skladen v podskupini bolnikov z visokim tveganjem, ki so imeli nizko izhodiščno vrednost MAP ali visok rezultat APACHE II, kar sta bili stratifikacijski spremenljivki (preglednica 3).
From Hour 3 to Hour 48, GIAPREZA or placebo were titrated to maintain MAP between 65 and 70 mmHg while reducing doses of other vasopressors. 
Od 3. do 48. ure so zdravilo GIAPREZA ali placebo titrirali do vzdrževanja MAP med 65 in 70 mmHg, hkrati pa so zmanjšali odmerke drugih vazopresorjev.
Placebo response rate 
Stopnja odziva pri placebu
83% of subjects had received two or more vasopressors and 47% three or more vasopressors prior to study drug administration. 
83 % preiskovancev je pred jemanjem študijskega zdravila prejemalo dva ali več vazopresorjev, 47 % pa tri ali več vazopresorjev.
If you notice any of these symptoms, seek medical advice immediately. 
Če se pojavi kateri izmed navedenih simptomov, takoj poiščite zdravniško pomoč.
What GIAPREZA is and what it is used for 2. 
Kaj je zdravilo GIAPREZA in za kaj ga uporabljamo 2.
Concentrate for solution for infusion 1 vial 
koncentrat za raztopino za infundiranje 1 viala